Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam gets $700m Sanofi investment, buys Sirna from Merck

This article was originally published in Scrip

Executive Summary

Sanofi's Genzyme business has invested $700m in a 12% stake in Alnylam Pharmaceuticals as part of an expansion of the alliance the two firms formed around Alnylam's lead product, patisiran, in 2012. Separately, Alnylam announced that it will acquire Sirna Therapeutics, a rival RNAi business, from Merck & Co, for $175m plus milestones.

You may also be interested in...



Up Front Or Back End? Considering The Best Structure For Milestone Fees

PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.

Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings

Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.

Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19

Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel